CollPlant Biotechnologies (CLGN) Price to Sales (2018 - 2026)

CollPlant Biotechnologies (CLGN) has reported Price to Sales for 9 consecutive years, with 10.35 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Price to Sales rose 628.01% year-over-year to 10.35; the trailing twelve-month figure through Mar 2026 stood at 1.94 (up 64.34% YoY), and the FY2025 full-year result was 0.76, down 90.56% from the prior year.
• Price to Sales fell to 10.35 in Q1 2026 per CLGN's latest filing, from 29.87 in the prior quarter.
• Across five years, Price to Sales topped out at 1422.99 in Q3 2024 and bottomed at 0.9 in Q2 2023.
• Historically, Price to Sales has averaged 135.69 across 5 years, with a median of 27.51 in 2024.
• The sharpest annual moves came in 2023 and 2024: Price to Sales tumbled 99.31% in 2023, then soared 2450.34% in 2024.
• Over 5 years, Price to Sales stood at 161.05 in 2022, then slumped by 84.8% to 24.48 in 2023, then grew by 2.73% to 25.14 in 2024, then increased by 18.81% to 29.87 in 2025, then plunged by 65.36% to 10.35 in 2026.
• According to Business Quant data, Price to Sales over the past three periods registered 10.35, 29.87, and 40.02 for Q1 2026, Q4 2025, and Q3 2025 respectively.